This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bulls Pile Into Nektar Therapeutics

By David Russell, reporter at OptionMonster

NEW YORK -- Nektar Therapeutics (NKTR) has been trending higher, and traders cleaned up in the name Thursday.

OptionMonster's tracking systems detected a spike of buying in the September 12 calls late in the morning, mostly for $1.25 and $1.35. These long calls locked in the price where shares can be purchased in the drug developer, giving them potentially explosive leverage in a rally.

That's exactly what happened Thursday. Nektar's stock was up some 5% when the option trades hit, then climbed 13% to close the session at $12.69. The calls, by contrast, shot up more than 75% to $2.40.

The stock has been swinging widely since late 2011 while making steadily higher lows. Thursday's bounce occurred around the same $11.10 level where it peaked in March and April, which could make some chart watchers think that it's in a bullish uptrend.

Volume approached 9,500 at the strike. Previous open interest was just 473 contracts, indicating that new capital was put to work.

Overall calls in the name outnumbered puts by an extremely bullish 52-to-1 ratio. Total option volume was 12 times greater than average.

Russell has no positions in NKTR.
This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports